Table 1.
Characteristics of patients in the training and validation cohorts.
| Features | Training Cohort PRJNA356761 (N = 51) |
Validation Cohort PRJEB23709 (N = 41) |
|---|---|---|
| Gender | NA | |
| Male | 26 (63%) | |
| Female | 15 (37%) | |
| Age | NA | |
| ≥60 | 26 (63%) | |
| <60 | 15 (37%) | |
| RECIST Response | ||
| CR | 3 (6%) | 4 (10%) |
| PR | 7 (14%) | 15 (36%) |
| SD | 16 (31%) | 6 (15%) |
| PD | 23 (45%) | 16 (39%) |
| NE | 2 (4%) | 0 (0%) |
| Survival time | ||
| PFS (days) | 111 (52~288) | 271 (80~891) |
| OS (days) | 484 (220~836) | 607 (169~1085) |
| Progressed | ||
| Yes | 26 (51%) | 29 (71%) |
| No | 25 (49%) | 12 (29%) |
| Status | ||
| Alive | 17 (33%) | 17 (41%) |
| Dead | 34 (67%) | 24 (59%) |
Note: Data were shown as N (%) or median (Q1~Q3). RECIST: Response Evaluation Criteria in Solid Tumors, CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease, NE: Not Evaluated, PFS: progression-free survival, OS: overall survival, and NA: Not applicable.